Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 5/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437038 | 0.84 | CA12 (0.47) | KDM4EALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL6438031 | 0.81 | PRKAG1 (0.47) | KDM4EALDH1A1HPGDPRKAG1PRKAA1 | |
| SCHEMBL5787645 | 0.81 | LMNA (0.48) | KDM4EALDH1A1HPGDPRKAG1PRKAA1 | |
| SCHEMBL6580792 | 0.77 | ATP6V1B1 (0.50) | MEN1KMT2AHSD17B10POLB | |
| SCHEMBL6581522 | 0.76 | HTR4 (0.39) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL6439902 | 0.74 | F2 (0.49) | KDM4EALDH1A1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL6437888 | 0.74 | HSD17B2 (0.50) | KDM4EALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL11310945 | 0.74 | LCK (0.58) | KDM4EALDH1A1HPGDLCKFYN | |
| SCHEMBL3387534 | 0.72 | ALDH1A1 (0.56) | KDM4EALDH1A1HPGDLCKFYN | |
| SCHEMBL7001451 | 0.72 | FLT3 (0.49) | KDM4EALDH1A1HPGDLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | FARINA CARLO (IT) | 2004-11-25 | — | — | US | disclosed |
| EP-1212317-B1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | NIKEM RESEARCH SRL (IT) | 2004-09-15 | — | — | EP | disclosed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | disclosed |
| EP-1212317-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GlaxoSmithKline S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001002388-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | MALT1, SOST, NFATC1 | KDM4E 2237/4885ALDH1A1 3540/4885HPGD 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.